Restless Leg Syndrome, Insomnia, and Depression in Hemodialysis Patients: Three Sides of a Triangle?

AUTHORS

Shiva Samavat 1 , 2 , Somayeh Fatemizadeh 3 , * , Hedieh Fasihi 3 , Marieh Farrokhy 3

1 Department of Nephrology, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

2 Chronic Kidney Disease Research Center (CKDRC), Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

3 Department of Internal Medicine, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

How to Cite: Samavat S, Fatemizadeh S, Fasihi H, Farrokhy M. Restless Leg Syndrome, Insomnia, and Depression in Hemodialysis Patients: Three Sides of a Triangle?, Nephro-Urol Mon. 2017 ; 9(3):e45076. doi: 10.5812/numonthly.45076.

ARTICLE INFORMATION

Nephro-Urology Monthly: 9 (3); e45076
Published Online: May 7, 2017
Article Type: Research Article
Received: December 26, 2016
Revised: February 26, 2017
Accepted: March 7, 2017
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Background: Restless leg syndrome (RLS) is a sensorimotor neurological disorder with high prevalence among patients with end-stage renal disease (ESRD) and is associated with sleep and mood disturbances. The current study evaluated the associations between RLS, depression and insomnia in patients undergoing hemodialysis.

Methods: The current cross sectional study collected sociodemographic, laboratory data, and medical history of 235 patients undergoing hemodialysis. RLS was assessed by a questionnaire designed by national institutes of health/international RLS study group (IRLSSG), depression by hospital anxiety depression scale (HADS), and insomnia by Pittsburgh sleep quality index (PSQI).

Results: The prevalence of RLS in patients undergoing hemodialysis was 23.4%; out of which 43.6% had severe and very severe RLS. Patients with RLS had a positive family history of RLS (P value < 0.001). There was no difference between the demographic and laboratory findings of the patients. In comparison to the patients without RLS, the patients with RLS had a higher prevalence of depression (63.6% vs. 42.2%, P value = 0.005), and more severe insomnia score (mean PSQI-score = 8.2 ± 4.9 vs. 6.2 ± 4 (P value = 0.009). The PSQI score were correlated with HADS score (P value < 0.001). In multivariate analysis, the link between RLS and depression depended on insomnia.

Conclusions: RLS is prevalent among patients undergoing dialysis and could lead to depression, even in the absence of insomnia. Thus, it seems that appropriate diagnosis and management of RLS would make a difference in quality of life of patients undergoing hemodialysis.

1. Background

Restless legs syndrome (RLS) is a sensory-motor neurologic disorder characterized by an uncomfortable sensation in legs along with obligatory leg movement to relief the complication (1).

Apart from the idiopathic form, secondary RLS is associated with iron deficiency, pregnancy, the Parkinson disease, and renal failure (2).

The prevalence of RLS is 5% to 10% in general population; however, the prevalence of RLS in patients with end-stage renal disease (ESRD) is estimated about 30% (ranging from 7% to 45%). Several factors influence the severity of RLS such as hypertension, female gender, weight, dialysis shift, age, and diabetes in patients undergoing hemodialysis (1). The effects of dialysis modality and adequacy on the severity of RLS are controversial.

RLS adversely affects sleep quality. More then 90% of patients with RLS have sleep disorders (3). On the other hand, epidemiologic data suggest higher prevalence of depression among patients with RLS (4-8). There is a strong relationship between insomnia and depression, as insomnia is a symptom of depression and also a risk factor to deteriorate depression (9). There are reports on the correlation between RLS and mental health, depression, decreased quality of life, and increased mortality among patient underwent transplantation or undergoing hemodialysis (1, 10-14). RLS is one of the most powerful causes of insomnia in chronic kidney diseases, however, sleep disorder cause depression (11, 15, 16). Data about the relationship between RLS, insomnia and depression are sparse and contradictory (17).

2. Objectives

The current study aimed at assessing the prevalence of RLS and the associated factors in patients undergoing hemodialysis as well as the correlation between RLS, insomnia, and depression; the study also hypothesized that RLS correlation with depression was independent of insomnia.

3. Methods

It was a cross sectional study on patients undergoing hemodialysis in 6 hemodialysis centers in Tehran, Iran. The study was approved by the ethical committee of chronic kidney disease research center (CKDRC).

From March to June 2015, a total of 325 hemodialysis patients aged 18 years and above who underwent hemodialysis for more than 3 months were enrolled. All participants in this study signed the informed written consent.

Patients with dementia, severe comorbidities (heart, lung, and liver diseases), and the ones who were not willing to participate were excluded.

Sociodemographic data (age, gender, body mass index (BMI), level of education, cause of ESRD, duration of dialysis, and dialysis shift), and drug use history (especially antidepressant, antianxiety, benzodiazepines, and dopaminergic agents) were recorded.

Latest laboratory data of the patients were recorded from their medical file including hemoglobin, serum iron, total iron binding capacity (TIBC), ferritin, calcium, phosphate, parathormone (iPTH), serum albumin, C-reactive protein (CRP), and uric acid. Dialysis adequacy was evaluated by single-pool Kt/V (spKt/V).

Previously trained physicians interviewed the patients and completed the following questionnaires: international restless legs syndrome study group (IRLSSG) and IRLSSG severity scale, Pittsburgh sleep quality index (PSQI), hospital anxiety and depression scale (HADS), and Charlson comorbidity index.

3.1. Assessment of RLS

RLS was assessed using IRLSSG questionnaire (18). The questionnaire was completed by a trained physician based on a face-to-face interview with patients. The severity of RLS was evaluated by 10 questions designed based on 6-option Likert scale from 0 to 5. Accordingly, severity of RLS was defined as followed: mild (0 to 10), moderate (11 to 20), severe (21 to 30), and very severe (31 to 40) (19).

3.2. Assessment of Depression

Depression was assessed by HADS as validated by Montazeri, et al., (20) among Iranian population. Depression was graded as normal (≤ 7), mild to moderate (8 to 10), and severe (≥ 11).

3.3. Assessment of Sleep Quality

The PSQI was used to assess insomnia in patients undergoing dialysis. PSQI was validated in Iranian population by Nazifi et al. (21). Sleep quality was defined poor in the scores more than 5. The score ≤ 5 was accepted as good sleep quality.

3.4. Statistical Analysis

Results were presented as mean ± standard deviation (SD) for the quantitative variables and summarized as frequencies and percentages for categorical variables. Quantitative and qualitative variables were measured by t and Chi-square tests, respectively. Logistic regression analysis was applied to evaluate the effect of RLS on sleep disorder and depression. For the statistic analysis, the SPSS software version 21 was used. P values less than 0.05 were considered significant.

4. Results

Among the 325 patients in 6 hemodialysis centers in Tehran, 235 were eligible and willing to participate. The mean age of the patients was 57 ± 16 years; 56.6% male. The mean duration on dialysis was 49.8 ± 65.7 months, with diabetes as the major cause of renal failure (42%).

Demographic and laboratory values of patients are shown in Table 1.

Table 1. Demographic and Paraclinical Data of the Study Subjects
Characteristics
Age, years (mean ± SD)57.3 ± 15.9
Male (%)56.6
BMI, kg/m2 (mean ± SD)25.4 ± 5.2
Cause of ESRD (%)
Diabetes42.9
Hypertension26.2
Glomerulonephritis9
ADPKD6.4
Obstructive uropathy5.2
Unknown10.3
Dialysis vintage, month (mean ± SD)49.8 ± 65.7
Kt/v > 1.2 (%)79.9
Hemoglobin, g/dL (mean ± SD)10.8 ± 1.8
Calcium, mg/dL (mean ± SD)8.6 ± 0.8
Phosphorus, mg/dL (mean ± SD)5.1 ± 1.4
iPTH, pg/mL (mean ± SD)243 ± 321
Albumin, g/dL (mean ± SD)4.08 ± 0.58
Systolic blood pressure, mmHg (mean ± SD)125 ± 21

Abbreviations: ADPKD: autosomal dominant polycystic kidney disease; BMI: body mass index; ESRD: end-stage renal disease; iPTH: parathormone; SD: standard deviation.

4.1. Restless Leg Syndrome

According to IRSSG questionnaire, 23.4% (n = 55) of the patients had RLS, and among them 16.7% had a family history of the RLS. The demographic and laboratory characteristics of the 2 groups are listed in Table 2. Comparing the data of patients with and without RLS indicated a significant difference only in the family history of the disorder between the groups (P value < 0.001).

Table 2. Demographic and Paralinical Findings
With RLSWithout RLSP Value
Age, years (mean ± SD)57.5 ± 15.557.3 ± 16.10.91
Male (%)47.359.40.122
Level of education
Illiterate28.320
Primary school28.341.10.187
High school diploma26.423.3
Higher education1715.6
BMI, kg/m2 (mean ± SD)25.9 ± 5.525.2 ± 5.10.443
Family history of RLS (%)16.72.20.000
Cause of ESRD (%)
Diabetes54.539.3
Hypertension18.228.6
ADPKD08.40.079
Glomerulonephritis12.77.9
Obstructive uropathy5.55.1
Unknown9.110.7
Dialysis vintage, month (mean ± SD)54.6 ±76.348.3 ± 62.30.58
Kt/v > 1.2 (%)83.378.80.561
Dialysis shift (%)
Morning56.441.90.169
Noon32.744.1
Night10.914
Charlson score (mean ± SD)5.52 ± 2.355.01 ± 2.150.151
Hemoglobin, g/dL (mean ± SD)10.6 ± 1.810.9 ± 1.80.424
Transferrin saturation, %, (mean)80490.296
Calcium, mg/dL (mean ± SD)8.5 ± 0.88.6 ± 0.80.252
Phosphorus, mg/dL (mean ± SD)5.1 ± 1.45 ± 1.40.725
iPTH, pg/mL (mean ± SD)242 ±413243± 2880.987
Vitamin D (mean ± SD)30.4±29.737.3± 26.40.204
Albumin, g/dL (mean ± SD)4.06±0.754.09 ± 0.530.74
Uric Acid, mg/dL (mean ± SD)6.9 ± 5.26.5± 4.60.703
Systolic blood pressure, mmHg (mean ± SD)127 ± 22124 ± 210.318

Abbreviations: ADPKD: autosomal dominant polycystic kidney disease; BMI: body mass index; ESRD: end-stage renal disease; iPTH: parathormone; SD: standard deviation

There were no significant differences between the groups regarding age, gender, cause of ESRD, duration of hemodialysis, dialysis adequacy, comorbidities based on Charlson index, and hypnotic-sedative drug consumption.

Laboratory findings of anemia, hyperparathyroidism, iron status, and serum albumin level were not significantly different between the groups.

Assessment of severity of RLS based on a 10-question IRSSG questionnaire indicated the following results: 10.9% of patients had mild RLS, 45.5% moderate RLS, 29.1% severe RLS and 14.5% of the patients experienced the symptoms very severely.

4.2. RLS and Depression

Among the studied patients undergoing hemodialysis, the average of HADS-score was 8.8 ± 7.7, and the prevalence of depression (HADS > 7) was 47.2% (n = 111).

Depression was more prevalent among the patients with RLS than the ones without RLS (63.3% vs. 42.2%, P value = 0.005). The severity of depression based on average HADS score was also significantly higher among the patients with RLS (12.8 ± 9 vs. 7.6 ± 6.8, P value < 0.001).

The prevalence of RLS was 31.5% and 16.1%, respectively, among the patients with and without depression (P value = 0.005). The more severe the depression, the higher the prevalence of RLS symptoms (Figure 1); 20 % and 35% of the patients with mild to moderate (HADS score 8 to 10) and severe (HADS score ≥ 11) depression showed RLS symptoms, respectively (P value = 0.005).

Figure 1. Prevalence of RLS at Different Levels of Depression Based on HADS Score

4.3. RLS and Insomnia

Among the cohort of patients undergoing hemodialysis, the mean PSQI-score was 6.7 ± 4.3, and the prevalence of insomnia (defined as PSQI > 5) was 53.6% (n = 126).

Although in patients with RLS the mean PSQI-score was higher than the ones without RLS (8.2 ± 4.9 vs. 6.2 ± 4, P value = 0.009), the prevalence of insomnia was not higher in patients with RLS (63.6% vs. 50.6%; P value = 0.09). However, patients with more severe RLS symptoms had higher prevalence of insomnia (Figure 2); 50% of the patient with mild RLS vs. 100% of the ones with very severe RLS symptoms had insomnia (P value = 0.01).

Figure 2. Prevalence of Insomnia at Different Levels of RLS

4.4. Depression and Insomnia

Insomnia was more prevalent among the patients with depression than the ones without depression (63.9% vs. 44.3%, P value = 0.003). On the other hand, the prevalence of depression was higher among the patients with insomnia than the ones without insomnia (56.3% vs. 36.6%, P value = 0.003).

Patients with depression had significantly higher scores on the PSQI than the ones without depression (8.1 ± 4.4 vs. 5.5 ± 6.3, P value < 0.001); furthermore, the mean HADS-score amongst the patients with insomnia was 11 ± 8.1, whereas it was 6.3 ± 6.3 in the patients without insomnia (P value < 0.001).

There was a strong correlation between the results of PSQI and HADS.

4.5. Multivariate Analyses

Multivariate logistic regression analysis demonstrated that RLS symptoms were only associated with severe depression (odds ratio (OR) = 2.9; confidence interval (CI) = 1.5 - 5.6; P value = 0.002). Sleep disturbance was not associated with RLS symptoms.

5. Discussion

In the current study, the prevalence of RLS among patients undergoing hemodialysis was 23.4%. Based on a systematic review on 30 articles in Iran by Ghanei-Gheshlagh et al., the overall prevalence of RLS in Iran was about 30% (95% CI: 24% - 36%) and its prevalence was 45% (95% CI: 33% - 57%) among patients with renal failure (22). Moreover, in a recent study in Iran, the prevalence of RLS in 136 patients undergoing hemodialysis was 37.4% (23).

There was no association between age, gender, cause of ESRD, duration of hemodialysis, dialysis adequacy, and comorbid diseases, and the prevalence of RLS in the current study. However, family history of RLS was significantly associated with its prevalence similar to the case in the study by Pizza et al. (24).

The current study found no association between diabetes and RLS, unlike the study by Lin et al. (2); the reason for this discrepancy is not clear. There was no association between the abnormalities in paraclinical parameters such as anemia, hyperparathyroidism, iron status, serum albumin, and dialysis adequacy and RLS. These findings demonstrated the fact that even under the light of paramedical parameters; the RLS is a problem that should be addressed separately.

About 44% of the study patients had severe and very severe RLS symptoms. RLS has major adverse impacts such as sleep disorder, depression, anxiety, sexual dysfunction, decreased quality of life, and cardiovascular mortality (25-28). Sleep disorders are prevalent among the patients undergoing hemodialysis (29), and about 54% of the current study patients had insomnia. On the other hand, depression was common and its relationship with RLS was independent of insomnia. Therefore, treatment and management of RLS might improve patients’ quality of life and decrease the prevalence of depression.

The current study had some limitations. First, it was a cross sectional study, therefore the cause and effect relationship between the findings of RLS, depression, and insomnia could not be verified. Second, the emotion-oriented coping with stress and other factors that might cause depression were not assessed.

5.1. Conclusion

RLS is prevalent among patients undergoing hemodialysis and could lead to depression even in the absence of insomnia. Thus, it seems that appropriate diagnosis and management of RLS would make a difference in the quality of life of patients undergoing dialysis. A well-designed clinical trail would help to find an effective treatment for RLS.

References

  • 1.

    Giannaki CD, Hadjigeorgiou GM, Karatzaferi C, Pantzaris MC, Stefanidis I, Sakkas GK. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int. 2014; 85(6) : 1275 -82 [DOI][PubMed]

  • 2.

    Lin CH, Wu VC, Li WY, Sy HN, Wu SL, Chang CC, et al. Restless legs syndrome in end-stage renal disease: a multicenter study in Taiwan. Eur J Neurol. 2013; 20(7) : 1025 -31 [DOI][PubMed]

  • 3.

    Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997; 12(1) : 61 -5 [DOI][PubMed]

  • 4.

    Sevim S, Dogu O, Kaleagasi H, Aral M, Metin O, Camdeviren H. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurol Neurosurg Psychiatry. 2004; 75(2) : 226 -30 [PubMed]

  • 5.

    Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord. 2001; 16(6) : 1159 -63 [PubMed]

  • 6.

    Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology. 2000; 54(5) : 1064 -8 [PubMed]

  • 7.

    Sukegawa T, Itoga M, Seno H, Miura S, Inagaki T, Saito W, et al. Sleep disturbances and depression in the elderly in Japan. Psychiatry Clin Neurosci. 2003; 57(3) : 265 -70 [DOI][PubMed]

  • 8.

    Lee HB, Hening WA, Allen RP, Kalaydjian AE, Earley CJ, Eaton WW, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci. 2008; 20(1) : 101 -5 [DOI][PubMed]

  • 9.

    Chang PP, Ford DE, Mead LA, Cooper-Patrick L, Klag MJ. Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol. 1997; 146(2) : 105 -14 [PubMed]

  • 10.

    Gigli GL, Adorati M, Dolso P, Piani A, Valente M, Brotini S, et al. Restless legs syndrome in end-stage renal disease. Sleep Med. 2004; 5(3) : 309 -15 [DOI][PubMed]

  • 11.

    Mucsi I, Molnar MZ, Ambrus C, Szeifert L, Kovacs AZ, Zoller R, et al. Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant. 2005; 20(3) : 571 -7 [DOI][PubMed]

  • 12.

    Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis. 1996; 28(3) : 372 -8 [PubMed]

  • 13.

    Molnar MZ, Novak M, Ambrus C, Szeifert L, Kovacs A, Pap J, et al. Restless Legs Syndrome in patients after renal transplantation. Am J Kidney Dis. 2005; 45(2) : 388 -96 [PubMed]

  • 14.

    Tanaka K, Morimoto N, Tashiro N, Hori K, Katafuchi R, Fujimi S. The features of psychological problems and their significance in patients on hemodialysis--with reference to social and somatic factors. Clin Nephrol. 1999; 51(3) : 161 -76 [PubMed]

  • 15.

    Novak M, Molnar MZ, Ambrus C, Kovacs AZ, Koczy A, Remport A, et al. Chronic insomnia in kidney transplant recipients. Am J Kidney Dis. 2006; 47(4) : 655 -65 [DOI][PubMed]

  • 16.

    Eryilmaz MM, Ozdemir C, Yurtman F, Cilli A, Karaman T. Quality of sleep and quality of life in renal transplantation patients. Transplant Proc. 2005; 37(5) : 2072 -6 [DOI][PubMed]

  • 17.

    Szentkiralyi A, Molnar MZ, Czira ME, Deak G, Lindner AV, Szeifert L, et al. Association between restless legs syndrome and depression in patients with chronic kidney disease. J Psychosom Res. 2009; 67(2) : 173 -80 [DOI][PubMed]

  • 18.

    Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003; 4(2) : 101 -19 [PubMed]

  • 19.

    Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003; 4(2) : 121 -32 [PubMed]

  • 20.

    Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S. The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version. Health Qual Life Outcomes. 2003; 1 : 14 [DOI][PubMed]

  • 21.

    Nazifi M, Mokarami H, Akbaritabar A. Psychometric properties of the persian translation of pittsburgh sleep quality index health scope. 2014; 3(2) : 15547

  • 22.

    Ghanei-Gheshlagh R, Parizad N, Zahednezhad H, Sarokhani M, Sayehmiri K, Baghi V. Prevalence of restless leg syndrome in iran: A systematic review and meta-analysis. J Sleep Sci. 2016; 1(3) : 131 -8

  • 23.

    Rohani M, Aghaei M, Jenabi A, Yazdanfar S, Mousavi D, Miri S. Restless legs syndrome in hemodialysis patients in Iran. Neurol Sci. 2015; 36(5) : 723 -7 [DOI][PubMed]

  • 24.

    Pizza F, Persici E, La Manna G, Campieri C, Plazzi G, Carretta E, et al. Family recurrence and oligo-anuria predict uremic restless legs syndrome. Acta Neurol Scand. 2012; 125(6) : 403 -9 [DOI][PubMed]

  • 25.

    Scherer JS, Combs SA, Brennan F. Sleep Disorders, Restless Legs Syndrome, and Uremic Pruritus: Diagnosis and Treatment of Common Symptoms in Dialysis Patients. Am J Kidney Dis. 2017; 69(1) : 117 -28 [DOI][PubMed]

  • 26.

    Dikici S, Bahadir A, Baltaci D, Ankarali H, Eroglu M, Ercan N, et al. Association of anxiety, sleepiness, and sexual dysfunction with restless legs syndrome in hemodialysis patients. Hemodial Int. 2014; 18(4) : 809 -18 [DOI][PubMed]

  • 27.

    Aritake-Okada S, Nakao T, Komada Y, Asaoka S, Sakuta K, Esaki S, et al. Prevalence and clinical characteristics of restless legs syndrome in chronic kidney disease patients. Sleep Med. 2011; 12(10) : 1031 -3 [DOI][PubMed]

  • 28.

    La Manna G, Pizza F, Persici E, Baraldi O, Comai G, Cappuccilli ML, et al. Restless legs syndrome enhances cardiovascular risk and mortality in patients with end-stage kidney disease undergoing long-term haemodialysis treatment. Nephrol Dial Transplant. 2011; 26(6) : 1976 -83 [DOI][PubMed]

  • 29.

    Einollahi B, Motalebi M, Rostami Z, Nemati E, Salesi M. Sleep quality among Iranian hemodialysis patients: a multicenter study. Nephrourol Mon. 2015; 7(1)[DOI][PubMed]

  • Copyright © 2017, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
    COMMENTS

    LEAVE A COMMENT HERE: